Therapeutic Landscape of Early Symptomatic Alzheimer's Disease Translated into Everyday Practice for Geriatric Providers.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or original clinical data.
PubMed 42148368 · doi:10.2147/CIA.S585263
What was done
This narrative review summarizes diagnostic biomarker advances and clinical considerations for amyloid-targeting therapies (donanemab and lecanemab) in patients with early symptomatic Alzheimer's disease (mild cognitive impairment and mild dementia). It focuses on practical application for geriatric healthcare providers, addressing treatment duration, adverse reaction management, patient counseling, and multidisciplinary care transitions.
What was found
The abstract reports no numerical findings or quantitative effect sizes. It qualitatively describes that donanemab and lecanemab slow disease progression as well as cognitive and functional decline, while emphasizing associated safety concerns including amyloid-related imaging abnormalities.
Why it matters
As disease-modifying therapies enter standard practice, geriatric clinicians require practical frameworks to balance therapeutic benefits against specific imaging-related risks and coordinate multidisciplinary care.
Limits
This is a narrative review presenting clinical guidance and expert perspective without original human subject data, systematic review methodology, or quantitative synthesis of trial endpoints or adverse event rates.
Cited by
- supports Alzheimer's disease accounts for approximately 60% to 80% of all dementia cases.